Detection and Characterization of Methylated Circulating Tumor DNA in Gastric Cancer DOI Open Access
Seung Young Seo, Sang Hee Youn, Jin‐Han Bae

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 7377 - 7377

Published: July 5, 2024

Gastric cancer is the fifth most common disease in world and fourth cause of death. It diagnosed through esophagogastroduodenoscopy with biopsy; however, there are limitations finding lesions early stages. Recently, research has been actively conducted to use liquid biopsy diagnose various cancers, including gastric cancer. Various substances derived from reflected blood. By analyzing these substances, it was expected that not only presence or absence but also type can be diagnosed. However, amount extremely small, even have variables depending on characteristics individual To overcome these, we collected methylated DNA fragments using MeDIP compared them normal plasma characterize tissue patients' plasma. We attempted blood As a result, confirmed consistency between approximately 41.2% found possibility diagnosing characterizing SFR 5'end-motif analysis.

Language: Английский

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine DOI Creative Commons
Ying Bao,

Dejing Zhang,

Huihui� Guo

et al.

Cancer Science, Journal Year: 2024, Volume and Issue: 115(4), P. 1060 - 1072

Published: Feb. 3, 2024

Abstract Liquid biopsy is emerging as a pivotal tool in precision oncology, offering noninvasive and comprehensive approach to cancer diagnostics management. By harnessing biofluids such blood, urine, saliva, cerebrospinal fluid, pleural effusions, this technique profiles key biomarkers including circulating tumor DNA, cells, microRNAs, extracellular vesicles. This review discusses the extended scope of liquid biopsy, highlighting its indispensable role enhancing patient outcomes through early detection, continuous monitoring, tailored therapy. While advantages are notable, we also address challenges, emphasizing necessity for precision, cost‐effectiveness, standardized methodologies broader application. The future trajectory set expand reach personalized medicine, fueled by technological advancements collaborative research.

Language: Английский

Citations

20
The omics technologies and liquid biopsies: Advantages, limitations, applications DOI Creative Commons
Daniele Magro,

Marika Venezia,

Carmela Rita Balistreri

et al.

Medicine in Omics, Journal Year: 2024, Volume and Issue: 11, P. 100039 - 100039

Published: May 21, 2024

Over the last few years, development of so-called omics technologies has greatly contributed to discovery new biomarkers and targets, embracing various fields from diagnostics therapy contributing meliorate advance precision personalized medicine. In addition classic omics, including genomics, transcriptomics, proteomics, metabolomics, newer-generation their platforms, such as microbiomics nutrigenomics, are emerging. parallel, use liquid biopsies, optimal biological samples, consisting in fluids (i.e. blood, saliva, urine) easy collect, whose components (cells, nucleic acids, exosome) can be analysed using throughput techniques, is becoming an attractive, because enables extrapolation big data via multi-omics technologies. Here, we report a brief description discussion technologies, by evidencing applications eventual limitations.

Language: Английский

Citations

11
The Potential of cfDNA as Biomarker: Opportunities and Challenges for Neurodegenerative Diseases DOI Creative Commons
Şeyma Aydın, Selçuk Özdemir, Ahmet Adıgüzel

et al.

Journal of Molecular Neuroscience, Journal Year: 2025, Volume and Issue: 75(1)

Published: March 13, 2025

Abstract Neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s (PD), multiple sclerosis (MS), and amyotrophic lateral (ALS), are characterized by the progressive gradual degeneration of neurons. The prevalence rates these disorders rise significantly with age. As life spans continue to increase in many countries, number cases is expected grow foreseeable future. Early precise diagnosis, along appropriate surveillance, continues pose a challenge. high heterogeneity neurodegenerative diseases calls for more accurate definitive biomarkers improve clinical therapy. Cell-free DNA (cfDNA), fragmented released into bodily fluids via apoptosis, necrosis, or active secretion, has emerged as promising non-invasive diagnostic tool various diseases. cfDNA can serve an indicator ongoing cellular damage mortality, neuronal loss, may provide valuable insights processes, progression, therapeutic responses. This review will first cover key aspects then examine recent advances its potential use biomarker disorders.

Language: Английский

Citations

1
Deep Learning-Based, Multiclass Approach to Cancer Classification on Liquid Biopsy Data DOI Creative Commons
Maksym A. Jopek, Krzysztof Pastuszak, Sebastian Cygert

et al.

IEEE Journal of Translational Engineering in Health and Medicine, Journal Year: 2024, Volume and Issue: 12, P. 306 - 313

Published: Jan. 1, 2024

Objective : The field of cancer diagnostics has been revolutionized by liquid biopsies, which offer a bridge between laboratory research and clinical settings. These tests are less invasive than traditional biopsies more convenient routine imaging methods. Liquid allow studying tumor-derived markers in bodily fluids, enabling the development precise diagnostic for screening, disease monitoring, therapy personalization. This study presents multiclass approach based on deep learning to analyze classify diseases blood platelet RNA. Its primary objective is enhance cancer-type diagnosis settings leveraging power combined with high-throughput sequencing biopsy. Ultimately, demonstrates potential this accurately identify patient's type cancer. xmlns:xlink="http://www.w3.org/1999/xlink">Methods developed method classifies patients using heatmap images, generated gene expression arranged according Kyoto Encyclopedia Genes Genomes pathways. images represent samples ovarian cancer, endometrial glioblastoma, non-small cell lung sarcoma, as well brain metastasis. xmlns:xlink="http://www.w3.org/1999/xlink">Results Our learning-based models reached 66.51% balanced accuracy when distinguishing those 6 sites origin 90.5% location-specific dataset where types from close locations were grouped. further investigated an explainable artificial intelligence-based (XAI) -SHAP. They returned set 60 genes highest impact models' decision-making process. xmlns:xlink="http://www.w3.org/1999/xlink">Conclusions results show that deep-learning methods promising opportunity detection could support clinicians' process finding solution black-box problem.

Language: Английский

Citations

8
Epigenetic modifications of cfDNA in liquid biopsy for the cancer care continuum DOI Creative Commons

Jodie Wong,

Rohit Muralidhar,

Liang Wang

et al.

Biomedical Journal, Journal Year: 2024, Volume and Issue: unknown, P. 100718 - 100718

Published: March 1, 2024

This review provides a comprehensive overview of the latest advancements in clinical utility liquid biopsy, with particular focus on epigenetic approaches aimed at overcoming challenges cancer diagnosis and treatment. It begins by elucidating key terms, including methylomics, fragmentomics, nucleosomics. The progresses to discuss methods for analyzing circulating cell-free DNA (cfDNA) highlights recent studies showcasing relevance modifications areas such as diagnosis, drug treatment response, minimal residual disease (MRD) detection, prognosis prediction. While acknowledging hurdles like complexity interpreting data absence standardization, charts path forward. advocates integration multi-omic through machine learning algorithms refine predictive models stresses importance collaboration among clinicians, researchers, scientists. Such cooperative efforts are essential fully leverage potential features practice.

Language: Английский

Citations

6
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy DOI Creative Commons

Baofa Yu,

Shengwen Shao, Wenxue Ma

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: unknown, P. 217350 - 217350

Published: Nov. 1, 2024

Pancreatic cancer remains one of the most challenging malignancies to treat due its late-stage diagnosis, aggressive progression, and high resistance existing therapies. This review examines latest advancements in early detection, therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, integration artificial intelligence (AI) data analysis. We highlight promising including microRNAs (miRNAs) circulating DNA (ctDNA), that offer enhanced sensitivity specificity for early-stage diagnosis when combined multi-omics panels. A detailed analysis TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM) contribute therapy by creating immunosuppressive barriers. also discuss interventions target these components, aiming improve drug delivery overcome evasion. Furthermore, AI-driven analyses are explored their potential interpret complex data, enabling personalized treatment strategies real-time monitoring response. conclude identifying key areas future research, clinical validation regulatory frameworks AI applications, equitable access innovative comprehensive approach underscores need integrated, outcomes pancreatic cancer.

Language: Английский

Citations

6
The expansion of liquid biopsies to vascular care: an overview of existing principles, techniques and potential applications to vascular malformation diagnostics DOI Creative Commons
Ann Mansur, Ivan Radovanovic

Frontiers in Genetics, Journal Year: 2024, Volume and Issue: 15

Published: Jan. 18, 2024

Vascular malformations are congenital lesions that occur due to mutations in major cellular signalling pathways which govern angiogenesis, cell proliferation, motility, and death. These have been widely studied oncology substrates for various small molecule inhibitors. Given their common molecular biology, there is now a potential repurpose these cancer drugs vascular malformation care; however, diagnosis required order tailour specific the individual patient’s mutational profile. Liquid biopsies (LBs), emerging as transformative tool field of oncology, hold significant promise this feat. This paper explores principles technologies underlying LBs evaluates revolutionize management malformations. The review begins by delineating fundamental LBs, focusing on detection analysis circulating biomarkers such cell-free DNA, tumor cells, extracellular vesicles. Subsequently, an in-depth technological advancements driving LB platforms presented. Lastly, highlights current state research applying malformations, uses aforementioned techniques conceptualize liquid biopsy framework unique clinical care.

Language: Английский

Citations

4
Identification of serum small non-coding RNA as biomarkers for endometrial receptivity DOI Creative Commons

Shaoyuan Xu,

Dong Hu,

Y.F. Ye

et al.

Genomics, Journal Year: 2025, Volume and Issue: 117(2), P. 111002 - 111002

Published: Jan. 21, 2025

Language: Английский

Citations

0
Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review DOI Open Access
Giuliana Ciappina, Enrica Toscano, Alessandro Ottaiano

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 2216 - 2216

Published: Feb. 28, 2025

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with metastatic disease posing significant therapeutic challenges. While anti-EGFR therapy has improved outcomes for patients RAS and BRAF wild-type tumors, resistance major hurdle, limiting treatment efficacy. The concept negative hyperselection emerged as refinement molecular profiling, identifying additional genomic alterations-such HER2 MET amplificationsand MAP2K1 mutations-that predict to agents. Studies incorporating these expanded assessments have demonstrated that nearly half RAS/BRAF tumors harbor alternative biomarkers, underscoring the need selection criteria. Liquid biopsies, particularly circulating tumor DNA (ctDNA) analysis, revolutionized precision oncology by providing minimally invasive, real-time assessment dynamics. ctDNA-based enables detection resistance-associated alterations, guiding decisions greater accuracy than conventional tissue biopsies. Recent trials support predictive value ctDNA-defined hyperselection, revealing superior stratified through liquid biopsy. This narrative review explores evolving role in first-line therapy, emphasizing integration ctDNA refine patient selection, enhance efficacy, pave way personalized strategies CRC.

Language: Английский

Citations

0
Radiomics and machine learning for predicting metachronous liver metastasis in rectal cancer DOI
Arunkumar Krishnan

World Journal of Gastrointestinal Oncology, Journal Year: 2025, Volume and Issue: 17(4)

Published: March 24, 2025

A recent study by Long et al used a predictive model to explore the efficacy of radiomics based on multiparametric magnetic resonance imaging in predicting metachronous liver metastasis (MLM) newly diagnosed rectal cancer (RC) patients. The machine learning algorithms, particularly random forest (RFM), appeared well-matched complex nature data. capabilities RFM, as evidenced area under curve 0.919 training cohort and 0.901 validation cohort, highlighted its potential clinical utility. However, we several methodological limitations, including excluding genomic markers, biases from retrospective design, limited generalizability due single-center study, variability image interpretation. We propose further investigation into integrating multi-omic data, conducting larger multicenter studies, utilizing advanced techniques. Additionally, importance interdisciplinary collaboration improve development advocate for cost-effectiveness analyses facilitate integration. Overall, this may early detection management MLM RC patients, with promising avenues future exploration. Ongoing research domain can potentially outcomes quality care

Language: Английский

Citations

0